I wrote about this company a while ago. Recently they had a press release about them announcing the first delivery of Actinium-225, a rare but promising cancer-fighting radio-isotope to the National Cancer Institute, a part of the National Institutes of Health (NIH), the federal government’s leading medical research organization. I have to tell you, the more I know about this company, the more I become more interested in investing in it. Of course, I’ve said so many times to myself that I would never invest in anything that’s traded at more than $1/share. But this one…Mmm looks like it becomes more and more appealing.

Here’s their price/share chart (starting from February 2004 - January 2005)

I know the price fluctuated a bit in the past 3 months, but hey it went up from under $2/share in September 2004 to $6/share in December. And I think 2005 should be a good year for them since they somehow decided to branch out to medical industry.

“…Isonics has received exclusive marketing and sales rights for all of the Actinium-225 produced by IPPE. Assuming that IPPE reaches target production levels over the next year, Isonics expects that this will nearly double the existing global supply of Actinium-225. Currently, research includes clinical trials for therapies for leukemia and lymphoma. Numerous pre-clinical results have been published demonstrating the potential application of Bismuth-213 as a therapeutic for metastatic disease, bone marrow transplant, as well as treatments of fungal and bacterial infection.
Independent medical researchers welcomed the projected Actinium supply increases. “Clinical results to date have looked very promising, but lack of availability of the isotope Actinium-225 and the present high cost for that which is available has greatly limited the research,” said Dr. Barbara Y. Croft, of the National Cancer Institute. “I am greatly encouraged that Isonics is working with IPPE to expand availability of Actinium-225, which will enable a greater number of promising research projects to proceed…”

That’s what they say in the article which was recently published in Business Wire. Very interesting, huh?

Quote of the Day:
Investors in the corporate bond market do not enjoy the same access to information as a car buyer or, dare I say, a fruit buyer. - SEC Chairman Arthur Levitt